The Real Anthony Fauci: Bill Gates, Big Pharma, and the Global War on Democracy and Public Health

by Robert F. Kennedy Jr.

Gold Rush In the summer of 2001, two months before the 9/11 World Trade Center attacks, the Department of Defense officially launched its drive to revive bioweapons research by sending a report to Congress, authored by Kadlec, pleading that the military’s system for developing vaccines to protect troops from anthrax, smallpox, and other exotic bioweapons “is insufficient and will fail.”67 Beginning with the 9/11 attack, the War on Terror triggered a tectonic shift in global security priorities and elephantine ripples in defense spending patterns across the globe as open democracies began shifting to a security state footing. The revival of US government interest in germ warfare opened new opportunities. The US biodefense budget went from $137 million in 1997 to $14.5 billion for 2001–2004.68 Every agency with a colorable claim to a National Security function paddled out frantically to barrel the money tsunami. Between 2001 and 2014, the United States spent around $80 billion on biodefense. Since germ weaponry was still illegal, vaccines became a critical euphemism for the revival of the multibillion-dollar bioweapons industry.